What we do ?
DemeRx is a clinical stage drug development company advancing two molecules for the treatment of substance use disorders
ibogaine is a lead molecule currently in clinical trials in the UK. The clinical program is funded by a joint venture agreement with atai Life Sciences.
noribogaine is the active metabolite of ibogaine and is a new chemical entity with robust patents for multiple therapeutic indications. Our current focus is for relapse prevention in alcohol use disorder.